Actively Recruiting
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
Led by Fu Xing Hospital, Capital Medical University · Updated on 2025-06-15
120
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effects of conservative treatment on people with retained products of conception (RPOC) and enhanced myometrial vascularity (EMV) following miscarriage or delivery. The study aims to determine whether natural resolution of RPOC can be achieved by combining it with EMV through conservative methods. This observational study is led by Fu Xing Hospital, Capital Medical University, and focuses on evaluating therapeutic outcomes after two menstrual cycles. Participants will receive conservative treatments such as mifepristone, GnRH-a, or expectant management after being diagnosed with RPOC and EMV. The main treatment period spans two menstrual cycles, after which therapeutic effects will be assessed. No additional interventions or comparison groups are mentioned, as this is an observational study monitoring natural and treatment-influenced resolution. During the study, participants will undergo transvaginal ultrasound at the end of the second menstrual cycle to check for resolution of RPOC. Researchers will also measure the disappearance rate of EMV immediately after completing conservative treatment. The study will track participants' response to treatment and monitor their health status, with a focus on treatment efficacy and safety throughout the observation period ending in late 2026.
CONDITIONS
Brief Title
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Recent history of miscarriage or delivery within the past 8 weeks
- Strong willingness to undergo conservative management
- Hemodynamically stable
- Signed informed consent form
You will not qualify if you...
- Heavy vaginal bleeding requiring immediate surgical intervention
- Active pelvic or systemic infection (e.g., fever over 38°C, elevated CRP or WBC)
- Severe dysfunction of heart, liver, or kidney
- Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
- Suspected ectopic pregnancy or gestational trophoblastic disease confirmed by ultrasound or beta-hCG levels
- Placenta accreta spectrum disorders diagnosed during current pregnancy
- History of uterine artery embolization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 menstrual cycles (approximately 8 weeks)
Participants who choose conservative management after miscarriage or delivery are observed to assess the resolution of retained products of conception (RPOC) and endometrial vascularity (EMV).
Ultrasound assessments at the end of the second menstrual cycle and immediately after completion of conservative treatment
Trial Site Locations
Total: 1 location
1
Hysteroscopy Center, Fuxing Hospital, Capital Medical University
Beijing, China, 100086
Actively Recruiting
Research Team
R
Rui Huang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here